ralometostat
Generic: Ralometostat
ralometostat: sourced relationships with 1 company · 1 clinical trial tracked.
ralometostat evidence translation
What we can confirm
1 tracked trial
What it means
Source-backed records connect ralometostat to TNGX; that link alone does not prove the drug works.
What to watch
Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected
Prepared research question
How could ralometostat → TNGX affect its developer, and what evidence supports the link?
Run cited research
Traceable citations · Unknowns marked
See linked entities and source evidence1 indications · 0 study sponsors
Related indications
Locally Advanced Solid Tumor
Study sponsors
No additional listed-company sponsor is linked.
Dated Pipeline Records (1)
| Company | Dated record stage |
|---|---|
| Tango Therapeutics, Inc. (TNGX) Locally Advanced Solid Tumor | Phase 1/Phase 2 |
Clinical Trial Registry Records (1)
A Phase 1/2, Multi-Center, Open-Label Study to Evaluate the Safety, Tolerability, and Preliminary Anti-tumor Activity of TNG908 in Patients With MTAP-deleted Advanced or Metastatic Solid Tumors
Primary endpoint: Phase 1:
Interventionalopen110 targetStarted 2022-03Completion 2025-1220 sites · France, United StatesTango Therapeutics, Inc.
Frequently asked questions
Which companies have sourced relationships with ralometostat?
ralometostat has dated SEC/FDA relationship records for Tango Therapeutics, Inc..
How many clinical trials involve ralometostat?
BioSniper tracks 1 clinical trial involving ralometostat.